Oral THC and CBD in Men and Women
Official title: Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women
Run by University of California, Los Angeles · NCT05067387 · Data updated 2026-11-12
This study tests how oral THC and CBD behave in the body and whether recently smoked THC can be detected in saliva, in adults who use cannabis but aren’t seeking treatment.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 55 Years |
| Sex | All |
| Enrollment | 22 (estimated) |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | August 13, 2026 |
| Main results expected | June 15, 2027 |
| Study ends | June 15, 2028 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT05067387 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 21-55 who use cannabis regularly but are not seeking treatment and meet the study’s health criteria.
✕Probably not a fit
Individuals with cannabis use disorder or other significant medical/psychiatric conditions, or those on interfering medications, may not benefit and could be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1, double-blind, placebo-controlled, within-subject study will measure the pharmacokinetics and pharmacodynamics of orally administered THC and CBD. It will also evaluate detection of recently smoked THC using oral-fluid biosensors and assess neurocognitive performance markers related to recent cannabis use. The study will determine how THC, CBD, and their metabolites appear in whole blood and how they affect pharmacodynamic outcomes. Participants will receive placebo, THC, CBD, or both, in a crossover design across study visits.
Why it matters
Potential benefit: Participants may gain access to early information about how THC and CBD behave in the body and how detection methods perform, which could inform safer use and testing.
How similar studies have gone: Previous research in cannabinoids has established pharmacokinetic and pharmacodynamic profiles, though this exact combination and within-subject, oral-delivery design is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening, * Not currently seeking treatment for their cannabis use * Have a Body Mass Index from 18.5 - 34kg/m2. * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: * Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine * Any other Axis I disorder * Report using other illicit drugs in the prior 4 weeks, other than cannabis. * Current use of any medications that may affect study outcomes * If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. * Pregnancy is exclusionary due to the possible effects of the study medication on fetal development. * History of an allergic reaction or adverse reaction to cannabis is exclusionary. * History of respiratory illness or current respiratory illness * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
Where it's running
-
University of California, Los Angeles
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Ziva Cooper — University of California, Los Angeles
- Study coordinator: Ziva Cooper, PhD
- Email: zcooper@mednet.ucla.edu
- Phone: 310-206-9942
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nitrous Oxide in Blood, Breath, and Urine After Different Exposures
This study tests how nitrous oxide appears in blood, breath, and urine after three different exposures in adults.
-
Ecological Momentary Intervention with Music or Reappraisal for Somatic Symptoms in SSD
We’re testing whether listening to music or using cognitive reappraisal in daily life can reduce how strongly somatic symptoms feel and how much they impair daily living for adults with Somatic Symptom Disorder.
-
Using hemadsorption to remove drugs in intoxicated ICU patients
This study is testing whether a special filter can help remove certain drugs from the blood of ICU patients who are unconscious due to drug overdose.
-
Peer-led support program for young drug abusers
This study is testing a new support program led by peers to help young people struggling with drug use quit and improve their overall well-being over a year.
-
Program to improve health and reduce substance use among Choctaw youth
This study is testing a nature-based program to help Choctaw youth aged 12-19 be more active, eat healthier, and reduce substance use by incorporating their cultural values.
-
A large biobank for acute and emergency medicine
This study is collecting health information and samples from patients with sudden illnesses in the Emergency Department to see if it can help improve treatments and predict how patients will do.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.